[1]
Shahid I, Almalki WH, Ibrahim MM, et al. Characterization of In vitro inhibitory effects of consensus short interference RNAs against non-structural 5B gene of hepatitis C virus 1a genotype. Indian J Med Microbiol 2018; Oct-Dec; 36(4): 494-503.
[http://dx.doi.org/10.4103/ijmm.IJMM_17_146.]]
[http://dx.doi.org/10.4103/ijmm.IJMM_17_146.]]
[2]
Shahid I, Ibrahim MM. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C. Curr Mol Med 2018; 18(7): 409-35.
[http://dx.doi.org/10.2174/1566524019666190104110439.]]
[http://dx.doi.org/10.2174/1566524019666190104110439.]]
[3]
Shahid I, AlMalki WH, AlRabia MW, et al. In vitro inhibitory analysis of consensus siRNAs against NS3 gene of hepatitis C virus 1a genotype. Asian Pac J Trop Med 2017; 10(7): 701-9. Epub 2017 Aug 8
[http://dx.doi.org/10.1016/j.apjtm.2017.07.011]
[http://dx.doi.org/10.1016/j.apjtm.2017.07.011]
[4]
Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018; 44(2): 143-60. Epub 2017 May 25.
[http://dx.doi.org/10.1080/1040841X.2017.1329277]
[http://dx.doi.org/10.1080/1040841X.2017.1329277]
[5]
Imran Shahid, Waleed Hassan AlMalki, Shaia Saleh R. Almalki, Ismail Muhammad AlTurkestany, Hassan Ali AlGhamdi, Saleh Ali AlMenshawi. Inhibition of Hepatitis C Virus Genotype 1a Non-Structural Proteins by Small Interference RNA in Human Hepatoma Cell Lines. Pharmacology & Pharmacy, Vol6 No11, Pub Date: November 24, 2015
[6]
Shahid I, AlMalki WH, Hafeez MH, Hassan S. Hepatitis C virus infection treatment: An era of game changer direct-acting antivirals and novel treatment strategies. Crit Rev Microbiol 2014; Nov 6; 1-13.
[7]
Shahid I, Ahmad W, Ijaz B, et al. Stable Huh-7 cell line development expressing HCV non-structural proteins of genotype 1a. J Virol Met 2013 Jan 4 ; 11: 4).
[8]
Imran Shahid, , Waleed H. AlMalki, Mohammed W. AlRabia, Muhammad H. Hafeez, and Muhammad Ahmed (2017). Hepatitis C Virus Infection
Treatment: Recent Advances and New Paradigms in the Treatment Strategies, Advances in Treatment of Hepatitis C and B, Prof. Naglaa Allam (Ed.),InTech,DOI: 10.5772/65873.Available from: In: https://www.intechopen.com/books/advances-in-treatment-of-hepatitis-c-and b/hepatitis-cvirusinfection-treatment-recent-advances-and-new-paradigms-in-the treatment-strategies
[9]
Imran Shahid, Munjed Mahmoud Ibrahim, Muhammad Usman Nawaz, Mohammad Tarque Imam, and, Waleed H. AlMalki. (June 20th 2018).Resistance-Associated Substitutions/Variants Correlate to Therapeutic Outcomes of Novel Direct-Acting Antivirals in Different HCV Genotype Treated Individuals, Genotyping Ibrokhim Abdurakhmonov, IntechOpen, DOI: 10.5772/intechopen.76395. Available from:https://www.intechopen.com/books/genotyping/resistance-associatedsubstitutions- variants-correlate-to-therapeutic-outcomes-of-novel-direct-actin
[10]
Imran Shahid. (October 10th 2018)..Introductory Chapter: Current and Emerging Anti-Hepatitis C Regimens: Hope or Hype, Hepatitis C, Imran
Shahid, IntechOpen., DOI: 10.5772/intechopen.81237 Available from: https://www.intechopen.com/books/hepatitisc- from-infection-to cure/introductory-chapter-current-and-emerging-anti-hepatitis-cregimens-hope-or-hype
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
47
1